Literature DB >> 21988165

Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et al.

John B Warren1, Kersti Oselin.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21988165      PMCID： PMC3243007          DOI： 10.1111/j.1365-2125.2011.03939.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  Incentives for drug development--the curious case of colchicine.

Authors:  Aaron S Kesselheim; Daniel H Solomon
Journal:  N Engl J Med       Date:  2010-04-14       Impact factor: 91.245

2.  Multinational medicines--ensuring drug quality in an era of global manufacturing.

Authors:  Susan Okie
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

3.  Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Authors:  Barbara M Davit; Patrick E Nwakama; Gary J Buehler; Dale P Conner; Sam H Haidar; Devvrat T Patel; Yongsheng Yang; Lawrence X Yu; Janet Woodcock
Journal:  Ann Pharmacother       Date:  2009-09-23       Impact factor: 3.154

4.  Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe.

Authors:  Atholl Johnston; Roland Asmar; Björn Dahlöf; Kate Hill; David Albert Jones; Jens Jordan; Michael Livingston; Graham Macgregor; Michael Sobanja; Panagiotis Stafylas; Enrico Agabiti Rosei; José Zamorano
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

5.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

6.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

7.  Use of confidence intervals in analysis of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534
  7 in total
  1 in total

Review 1.  Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.